TransCode Therapeutics, Inc. (RNAZ) |
|
0.5885 -0.102 (-14.8%)
|
09-27 16:00 |
|
Open: |
0.621 |
Pre. Close: |
0.6907 |
|
High:
|
0.68 |
Low:
|
0.574 |
|
Volume:
|
5,015,308 |
Market Cap:
|
1(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:21:50 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.53 One year: 3.73 |
| Support: |
Support1: 0.5 Support2: 0.41 |
| Resistance: |
Resistance1: 2.16 Resistance2: 3.2 |
| Pivot: |
0.88 |
| Moving Average: |
MA(5): 1.03 MA(20): 1.03
MA(100): 2.68 MA(250): 8.05 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3  |
| Stochastic oscillator: |
%K(14,3): 28.7 %D(3): 32.4 |
| RSI: |
RSI(14): 42.6 |
| 52-week: |
High: 31 Low: 0.5 |
| Average Vol(K): |
3-Month: 2,472 (K) 10-Days: 14,453 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RNAZ ] has closed above bottom band by 34.4%. Bollinger Bands are 41.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.68 - 0.69 |
0.69 - 0.69 |
|
Low:
|
0.57 - 0.57 |
0.57 - 0.57 |
|
Close:
|
0.58 - 0.59 |
0.59 - 0.59 |
|
Company Description |
|
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts. |
Headline News |
Tue, 26 Sep 2023
Why Transcode Therapeutics (RNAZ) Stock Is Down Nearly 70% - TransCode Therapeutics (NASDAQ:RNAZ) - Benzinga
Mon, 25 Sep 2023
TransCode Therapeutics Announces Pricing of $8 Million Public Offering - Yahoo Finance
Mon, 25 Sep 2023
Healthcare Stocks on the Move Monday: RNAZ, VACC, BPTS, CARM, SCYX, MORF, AXLA, APLT - InvestorsObserver
Mon, 25 Sep 2023
The Intriguing Event of a Stock Trading Halt - Best Stocks
Mon, 25 Sep 2023
Trading Halt on NASDAQ Understanding the Reasons and Impact - Best Stocks
Mon, 25 Sep 2023
The Implications and Reasons Behind Trading Halts - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
29.5 (%) |
|
% Held by Institutions
|
1.5 (%) |
|
Shares Short
|
24 (K) |
|
Shares Short P.Month
|
15 (K) |
Stock Financials |
|
EPS
|
-24.73 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.07 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-128 |
|
Return on Equity (ttm)
|
-256 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-10.05 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-17 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-0.03 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.55 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.07 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
